The Benchmark Company initiated coverage on OmniAb with a new price target

4/21/23 7:43:22 AM ET

Biotechnology: Commercial Physical & Biological Resarch

Health Care

The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OABI

Date	Price Target	Rating	Analyst
11/29/2023	$6.00	Outperform	RBC Capital Mkts
4/21/2023	$8.00	Buy	The Benchmark Company
4/13/2023	$10.00	Buy	Craig Hallum
2/22/2023	$10.00	Outperform	Cowen
2/13/2023	$11.00	Buy	H.C. Wainwright